Marco Roberto1, Dragana Radovanovic2, Carmelo Buttà1,3, Gregorio Tersalvi1,4, Joël Krüll1, Paul Erne2, Hans Rickli5, Giovanni Battista Pedrazzini1, Marco Moccetti1. 1. Cardiology Department, Cardiocentro Ticino, Lugano, Switzerland. 2. AMIS Plus Data Centre, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland. 3. Unità Operativa Complessa di Cardiologia, Barone Romeo Hospital, Patti, Italy. 4. Internal Medicine Department, Hirslanden Klinik St. Anna, Luzern, Switzerland. 5. Cardiology Department, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Abstract
OBJECTIVES: Despite guideline recommendations, previous reports, coming mainly from outside Europe, showed low rates of prescriptions for dual antiplatelet therapy (DAPT) in patients with acute myocardial infarction (AMI) undergoing surgical revascularization. The present study assesses this issue in the era of potent P2Y12 inhibitors in Switzerland. METHODS: All patients with a diagnosis of AMI included in the Acute Myocardial Infarction in Switzerland Plus Registry from January 2014 to December 2019 were screened; 9050 patients undergoing either percutaneous (8727, 96.5%) or surgical (323, 3.5%) revascularization were included in the analysis. RESULTS: Surgically treated patients were significantly less likely to receive DAPT at discharge (56.3% vs 96.7%; P < 0.001). Even when discharged with a prescription for DAPT, those patients were significantly less likely to receive a regimen containing a new P2Y12 inhibitor (67/182 [36.8%] vs 6945/8440 [83.2%]; P < 0.001). At multivariate analysis, surgical revascularization was independently associated with a lower likelihood of receiving a prescription for DAPT at discharge (odds ratio 0.03, 95% confidence interval 0.02-0.06). CONCLUSIONS: DAPT prescriptions for patients with AMI undergoing surgical revascularization are not in line with current guideline recommendations. Efforts are necessary to clarify the role of DAPT for secondary prevention in these patients and increase the confidence of treating physicians in guideline recommendations. CLINICAL TRIAL REGISTRATION: Acute Myocardial Infarction in Switzerland Plus Registry; registration number at ClinicalTrials.gov: NCT01305785.
OBJECTIVES: Despite guideline recommendations, previous reports, coming mainly from outside Europe, showed low rates of prescriptions for dual antiplatelet therapy (DAPT) in patients with acute myocardial infarction (AMI) undergoing surgical revascularization. The present study assesses this issue in the era of potent P2Y12 inhibitors in Switzerland. METHODS: All patients with a diagnosis of AMI included in the Acute Myocardial Infarction in Switzerland Plus Registry from January 2014 to December 2019 were screened; 9050 patients undergoing either percutaneous (8727, 96.5%) or surgical (323, 3.5%) revascularization were included in the analysis. RESULTS: Surgically treated patients were significantly less likely to receive DAPT at discharge (56.3% vs 96.7%; P < 0.001). Even when discharged with a prescription for DAPT, those patients were significantly less likely to receive a regimen containing a new P2Y12 inhibitor (67/182 [36.8%] vs 6945/8440 [83.2%]; P < 0.001). At multivariate analysis, surgical revascularization was independently associated with a lower likelihood of receiving a prescription for DAPT at discharge (odds ratio 0.03, 95% confidence interval 0.02-0.06). CONCLUSIONS: DAPT prescriptions for patients with AMI undergoing surgical revascularization are not in line with current guideline recommendations. Efforts are necessary to clarify the role of DAPT for secondary prevention in these patients and increase the confidence of treating physicians in guideline recommendations. CLINICAL TRIAL REGISTRATION: Acute Myocardial Infarction in Switzerland Plus Registry; registration number at ClinicalTrials.gov: NCT01305785.
Authors: Philip Urban; Ian T Meredith; Alexandre Abizaid; Stuart J Pocock; Didier Carrié; Christoph Naber; Janusz Lipiecki; Gert Richardt; Andres Iñiguez; Philippe Brunel; Mariano Valdes-Chavarri; Philippe Garot; Suneel Talwar; Jacques Berland; Mohamed Abdellaoui; Franz Eberli; Keith Oldroyd; Robaayah Zambahari; John Gregson; Samantha Greene; Hans-Peter Stoll; Marie-Claude Morice Journal: N Engl J Med Date: 2015-10-14 Impact factor: 91.245
Authors: Claes Held; Nils Asenblad; Jean Pierre Bassand; Richard C Becker; Christopher P Cannon; Marc J Claeys; Robert A Harrington; Jay Horrow; Steen Husted; Stefan K James; Kenneth W Mahaffey; José C Nicolau; Benjamin M Scirica; Robert F Storey; Marius Vintila; Joseph Ycas; Lars Wallentin Journal: J Am Coll Cardiol Date: 2010-12-30 Impact factor: 24.094
Authors: Jared P Beller; William Z Chancellor; J Hunter Mehaffey; Robert B Hawkins; Matthew R Byler; Alan M Speir; Mohammed A Quader; Andy C Kiser; Leora T Yarboro; Gorav Ailawadi; Nicholas R Teman Journal: Ann Thorac Surg Date: 2020-02-11 Impact factor: 4.330
Authors: Peter K Smith; Lawrence T Goodnough; Jerrold H Levy; Robert S Poston; Mary A Short; Govinda J Weerakkody; Leroy A Lenarz Journal: J Am Coll Cardiol Date: 2012-05-23 Impact factor: 24.094
Authors: Niels P G Hoedemaker; Peter Damman; Jan Paul Ottervanger; Jan Henk E Dambrink; A T Marcel Gosselink; Elvin Kedhi; Evelien Kolkman; Robbert J de Winter; Arnoud W J van 't Hof Journal: Eur Heart J Cardiovasc Pharmacother Date: 2018-04-01
Authors: Keith A A Fox; Shamir R Mehta; Ron Peters; Feng Zhao; Nasser Lakkis; Bernard J Gersh; Salim Yusuf Journal: Circulation Date: 2004-08-16 Impact factor: 29.690
Authors: Dragana Radovanovic; Burkhardt Seifert; Philip Urban; Franz R Eberli; Hans Rickli; Osmund Bertel; Milo A Puhan; Paul Erne Journal: Heart Date: 2013-11-01 Impact factor: 5.994
Authors: Jean-Philippe Collet; Holger Thiele; Emanuele Barbato; Olivier Barthélémy; Johann Bauersachs; Deepak L Bhatt; Paul Dendale; Maria Dorobantu; Thor Edvardsen; Thierry Folliguet; Chris P Gale; Martine Gilard; Alexander Jobs; Peter Jüni; Ekaterini Lambrinou; Basil S Lewis; Julinda Mehilli; Emanuele Meliga; Béla Merkely; Christian Mueller; Marco Roffi; Frans H Rutten; Dirk Sibbing; George C M Siontis Journal: Eur Heart J Date: 2021-04-07 Impact factor: 29.983
Authors: Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker Journal: Eur Heart J Date: 2015-08-29 Impact factor: 29.983